ANDA 212402, held by Zydus Pharmaceuticals (USA). Metoprolol Tartrate.
As of Nov 22, 2026, ANDA 212402 (Metoprolol Tartrate), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Apr 19, 2023, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 19, 2023 | Original application | Approved | None posted |
| Metoprolol Tartrate25MG · tablet;oral | Metoprolol Tartrate | Discontinued |
| Metoprolol Tartrate50MG · tablet;oral | Metoprolol Tartrate | Discontinued |
| Metoprolol Tartrate100MG · tablet;oral | Metoprolol Tartrate | Discontinued |
| Nov 21, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 27, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 19, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters